BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 9594298)

  • 1. Detection of neuroblastoma cells in blood by reverse transcriptase-polymerase chain reaction.
    Gao Y; Li G; Zhang X; Xu Q; Zheng B
    Chin Med J (Engl); 1997 May; 110(5):341-5. PubMed ID: 9594298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of protein gene product 9.5 and tyrosine hydroxylase in childhood small round cell tumors.
    Wang Y; Einhorn P; Triche TJ; Seeger RC; Reynolds CP
    Clin Cancer Res; 2000 Feb; 6(2):551-8. PubMed ID: 10690538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical implications of minimal disease in the bone marrow and peripheral blood in neuroblastoma.
    Shono K; Tajiri T; Fujii Y; Suita S
    J Pediatr Surg; 2000 Oct; 35(10):1415-20. PubMed ID: 11051140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive detection of rare circulating neuroblastoma cells by the reverse transcriptase-polymerase chain reaction.
    Mattano LA; Moss TJ; Emerson SG
    Cancer Res; 1992 Sep; 52(17):4701-5. PubMed ID: 1380888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical application of minimal residual neuroblastoma cell detection by reverse transcriptase-polymerase chain reaction.
    Kuroda T; Saeki M; Nakano M; Mizutani S
    J Pediatr Surg; 1997 Jan; 32(1):69-72. PubMed ID: 9021573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Usefulness of tyrosine hydroxylase mRNA for diagnosis and detection of minimal residual disease in neuroblastoma.
    Ito R; Asami S; Kagawa S; Motohashi S; Shichino H; Chin M; Yoshida Y; Nemoto N; Mugishima H; Suzuki T
    Biol Pharm Bull; 2004 Mar; 27(3):315-8. PubMed ID: 14993794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of neuroblastoma cells in bone marrow and peripheral blood at diagnosis by the reverse transcriptase-polymerase chain reaction for tyrosine hydroxylase mRNA.
    Miyajima Y; Kato K; Numata S; Kudo K; Horibe K
    Cancer; 1995 Jun; 75(11):2757-61. PubMed ID: 7743482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma.
    Pession A; Libri V; Sartini R; Conforti R; Magrini E; Bernardi L; Fronza R; Olivotto E; Prete A; Tonelli R; Paolucci G
    Oncol Rep; 2003; 10(2):357-62. PubMed ID: 12579272
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of neuroblastoma cells during clinical follow up: advanced flow cytometry and rt-PCR for tyrosine hydroxylase using both conventional and real-time PCR.
    Esser R; Glienke W; Bochennek K; Erben S; Quaiser A; Pieper C; Eggert A; Schramm A; Astrahantseff K; Hansmann ML; Schwabe D; Klingebiel T; Koehl U
    Klin Padiatr; 2011 Nov; 223(6):326-31. PubMed ID: 22095188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular detection of GAGE expression in peripheral blood and bone marrow: utility as a tumor marker for neuroblastoma.
    Cheung IY; Cheung NK
    Clin Cancer Res; 1997 May; 3(5):821-6. PubMed ID: 9815755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular detection of dopamine decarboxylase expression by means of reverse transcriptase and polymerase chain reaction in bone marrow and peripheral blood: utility as a tumor marker for neuroblastoma.
    Bozzi F; Luksch R; Collini P; Gambirasio F; Barzanò E; Polastri D; Podda M; Brando B; Fossati-Bellani F
    Diagn Mol Pathol; 2004 Sep; 13(3):135-43. PubMed ID: 15322424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year.
    Burchill SA; Lewis IJ; Abrams KR; Riley R; Imeson J; Pearson AD; Pinkerton R; Selby P
    J Clin Oncol; 2001 Mar; 19(6):1795-801. PubMed ID: 11251011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TH and DCX mRNAs in peripheral blood and bone marrow predict outcome in metastatic neuroblastoma patients.
    Yáñez Y; Hervás D; Grau E; Oltra S; Pérez G; Palanca S; Bermúdez M; Márquez C; Cañete A; Castel V
    J Cancer Res Clin Oncol; 2016 Mar; 142(3):573-80. PubMed ID: 26498952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Useful markers for detecting minimal residual disease in cases of neuroblastoma.
    Ootsuka S; Asami S; Sasaki T; Yoshida Y; Nemoto N; Shichino H; Chin M; Mugishima H; Suzuki T
    Biol Pharm Bull; 2008 Jun; 31(6):1071-4. PubMed ID: 18520032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR.
    Wagner LM; Burger RA; Guichard SM; Raimondi SC; Santana VM; Furman WL; Barnette P; Danks MK
    J Pediatr Hematol Oncol; 2006 Oct; 28(10):635-41. PubMed ID: 17023822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measuring circulating neuroblastoma cells by quantitative reverse transcriptase-polymerase chain reaction analysis.
    Cheung IY; Sahota A; Cheung NK
    Cancer; 2004 Nov; 101(10):2303-8. PubMed ID: 15484213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of the PGP9.5 and tyrosine hydroxylase mRNAs for minimal residual neuroblastoma cells in bone marrow and peripheral blood.
    Yanagisawa TY; Sasahara Y; Fujie H; Ohashi Y; Minegishi M; Itano M; Morita S; Tsuchiya S; Hayashi Y; Ohi R; Konno T
    Tohoku J Exp Med; 1998 Mar; 184(3):229-40. PubMed ID: 9591338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganglioside GM2/GD2 synthetase mRNA is a marker for detection of infrequent neuroblastoma cells in bone marrow.
    Hoon DS; Kuo CT; Wen S; Wang H; Metelitsa L; Reynolds CP; Seeger RC
    Am J Pathol; 2001 Aug; 159(2):493-500. PubMed ID: 11485908
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma.
    Parareda A; Gallego S; Roma J; Llort A; Sábado C; Gros L; De Toledo JS
    Oncol Rep; 2005 Oct; 14(4):1021-7. PubMed ID: 16142367
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.